5) Describe the Issuer’s Business, Products and Services
Vaccex is a development stage biotechnology company focused on developing and commercializing immunotherapy products. Our lead product (VX001) is a sustained release formulation of a potent TLR7/8 agonist that works in synergy with fractionated radiotherapy (RT). VX001 is a potent stimulator of the innate immune system and intra- tumoral injection of VX001 in combination with RT causes tumor regression, long-term survival and prevention of cancer upon re-challenges in syngenic mouse models. VX001 and RT is therefore a promising treatment regimen for
clinical testing in metastatic solid tumor patients and the treatment regimen is being prepared for clinical proof of concept studies in 2020.
As the field of immunotherapy continues to evolve, the flexibility of the controlled and sustained release formulation has allowed Vaccex to develop innovative treatment strategies and we have demonstrated preclinical synergies with antibodies and chemotherapy in addition to radiotherapy.
Vaccex is initially focused on three product-related areas in various stages of development, which we believe will provide the greatest opportunity to have a significant impact on patients and their families:
1. Metastasized colorectal cancer
2. Metastasized breast cancer
3. Personalized intra-tumoral therapies
All three product areas are anchored in the Company’s controlled and sustained release formulation platform which can be flexibly designed to accommodate precise dosing schedules, including individual dosing requirements, for various cancers. Intra-tumoral delivery of anti-cancer drugs is an effective way of avoiding systemically induced adverse events, directly targeting the immunosuppressive tumor microenvironment and to potently stimulate the immune system.
$VCEX!
